BiotechTube

Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalin

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Abdominal Pain

Conditions

Abdominal Pain, Surgical Adhesions

Trial Timeline

Mar 1, 2006 → Aug 1, 2008

NCT ID
NCT00310765

About Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalin

Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalin is a approved stage product being developed by Pfizer for Abdominal Pain. The current trial status is terminated. This product is registered under clinical trial identifier NCT00310765. Target conditions include Abdominal Pain, Surgical Adhesions.

What happened to similar drugs?

5 of 20 similar drugs in Abdominal Pain were approved

Approved (5) Terminated (0) Active (15)
✅MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
✅Tigecycline + Imipenem/cilastatinPfizerApproved
✅tigecyclinePfizerApproved
✅Fibrinogen concentrate + Fresh Frozen PlasmaCSLApproved
✅Sevoflurane + propofol + remifentanilBaxterApproved
🔄PD-1 Inhibitors + Irinotecan + Capecitabine tabletsJiangsu Hengrui MedicinePhase 3
🔄Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00310765ApprovedTerminated

Competing Products

20 competing products in Abdominal Pain

See all competitors
ProductCompanyStageHype Score
PD-1 Inhibitors + Irinotecan + Capecitabine tabletsJiangsu Hengrui MedicinePhase 3
36
HR021618 + PlaceboJiangsu Hengrui MedicinePhase 2
35
Ticagrelor + PlaceboAstraZenecaPhase 2
35
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactamMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3
40
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mgMerckPhase 3
40
CXA-201 and metronidazole + MeropenemMerckPhase 3
40
Imipenem+Cilastatin/RelebactamMerckPhase 3
40
CXA-101/ tazobactam and metronidazole + meropenem plus saline placeboMerckPhase 2
35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for MetronidazoleMerckPhase 2
35
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral TabletMerckPhase 2/3
42
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 WeeksMerckPhase 3
40
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved
43
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 WeeksMerckPhase 3
40
LYS228 + Standard of care therapyNovartisPhase 2
27
ACZ885 + PlaceboNovartisPhase 2
27
Evolocumab + PlaceboAmgenPhase 1
36
tigecyclinePfizerPhase 3
40
recombinant human growth hormonePfizerPhase 3
40
Ceftazidime-avibactam + metronidazole + MeropenemPfizerPhase 3
40